Study Summary
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Want to learn more about this trial?
Request More InfoInterventions
MB-CART19.1BIOLOGICAL
MB-CART19.1 consists of autologous CD19 Chimeric Antigen Receptor (CAR) transduced CD4/CD8 enriched T cells targeting CD19-positive tumor cells in b cell malignancies
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Charité - University clinic, pediatric clinic with focus on oncology and hematology | Berlin | Germany | |
| Universitätsklinikum Erlangen | Erlangen | Germany | |
| University medicine Goettingen, Clinic of hematology and medical oncology | Göttingen | Germany | |
| Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University | Munich | Germany | |
| Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie | Münster | Germany | |
| Universitätsklinikum Münster - Medizinische Klinik A / KMT Zentrum | Münster | Germany | |
| Tuebingen University clinic, medical university clinic for internal medicine | Tübingen | Germany | |
| University clinic for children and youth medicine | Tübingen | Germany | |
| University clinic, pediatric hematology and oncology | Würzburg | Germany |